LY2584702 (tosylate) – 1 mg

Brand:
Cayman
CAS:
1082949-68-5
Storage:
-20
UN-No:
De Minimis - 3077 / 9

p70 Ribosomal S6 kinase (p70S6K) is a serine/threonine kinase that is activated by insulin and growth factors through PI3K and mTORC1 signaling pathways. LY2584702 is a selective, cell-permeable p70S6K inhibitor (IC50 = 4 nM). It blocks phosphorylation of p70S6K in primary rat hepatocytes without affecting the phosphorylation of other signaling kinases, including GSK-3β and ERK1/2.{30510} LY2584702 inhibits phosphorylation of p70S6K in HCT116 colon cancer cells (IC50 = 0.1-0.24 μM in vitro) and demonstrates significant antitumor efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models.{30512} It also reverses the effects of mTORC1 hyperactivation on triglyceride metabolism in human hepatoma cells.{30511} LY2584702, alone or in combination with the mTOR inhibitor everolimus (Item No. 11597), has been evaluated in clinical trials against solid tumors.{30512,30509}  

 

SKU: - Category:

Description

A selective, cell-permeable p70S6K inhibitor (IC50 = 4 nM) that blocks phosphorylation of p70S6K in primary rat hepatocytes; demonstrates significant antitumor efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models


Formal name: 4-[4-[4-[4-fluoro-3-(trifluoromethyl)phenyl]-1-methyl-1H-imidazol-2-yl]-1-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine, 4-methylbenzenesulfonate

Synonyms:  LYS6K2

Molecular weight: 617.6

CAS: 1082949-68-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|S6K||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling||Research Area|Cancer|Metabolism||Research Area|Cell Biology|Cell Signaling|PI3K/Akt/mTOR Signaling